Table 1.

Molecular Genetic Testing Used in WARS2 Deficiency

Gene 1MethodProportion of Pathogenic Variants 2 Detectable by Method
WARS2 Sequence analysis 3100% 4, 5
Gene-targeted deletion/duplication analysis 6None reported 4, 7
1.
2.

See Molecular Genetics for information on variants detected in this gene.

3.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4.

Data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

5.

Includes the hypomorphic variant c.37T>G (p.Trp13Gly), which is only disease causing when present in trans with loss-of-function pathogenic variants [Ilinca et al 2022, Skorvanek et al 2022]. Of note, the p.Trp13Gly variant is typically not detected by standard filtering criteria of exome sequencing. Therefore, if another pathogenic WARS2 variant is detected in the heterozygous state, using additional and/or modified filters to specifically confirm/exclude the presence of the p.Trp13Gly hypomorphic variant in trans is recommended (see Molecular Genetics).

6.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

7.

One individual with a 36-kb deletion including exon 2 of WARS2 had a severe fatal neonatal form of disease that might also be explained by the presence of another variant (p.Val349Leu) with a more significant deleterious effect and possibly other modifiers. Additionally, two sibs with levodopa-responsive parkinsonism had the p.Trp13Gly variant in compound heterozygosity with an exon 2 deletion. Deletion of exon 2 is predicted to result in an in-frame deletion of 86 amino acids (p.Lys31_Q116del), consistent with a loss-of-function effect [Wortmann et al 2017, Skorvanek et al 2022].

From: WARS2 Deficiency

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.